|

A First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma

RECRUITINGN/ASponsored by Coherence Neuro Australia Pty Limited
Actively Recruiting
PhaseN/A
SponsorCoherence Neuro Australia Pty Limited
Started2026-05
Est. completion2026-09
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

The goal of this clinical trial is to collect data on the use of the CIPHER System when used by a surgeon during brain tumor removal. The main questions it aims to answer are: * To evaluate the safety of the CIPHER System when used during brain tumor surgery (Primary) * To evaluate the function of the electrodes under recording and stimulating conditions during surgery (Secondary) Participants will undergo standard-of-care surgery to remove their tumor. Just before the tumor is removed, the CIPHER System will be tested on the main tumor and the surrounding margin areas. Participants will be monitored during standard hospital visits occurring during the recovery period after surgery as well as two- and six-weeks after surgery.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Newly diagnosed supratentorial glioma requiring resection
* Glioma mass reaches or close to cortical surface
* Adults aged 18-75
* Planned for open craniotomy under Total Intravenous Anesthesia (TIVA)
* Patient able to provide informed consent
* Performance status: Eastern Cooperative Oncology Group (ECOG) scale 0-2

Exclusion Criteria:

* Prior craniotomy at the same anatomical location
* Plan for awake craniotomy
* Any history of seizures prior to craniotomy
* Any history of coagulopathy or coagulation disorders
* Pregnant status during craniotomy

Conditions5

BrainCancerElectrocorticographyGliomaTumor

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.